Companies · Pharmaceuticals

Verona Pharma plc

London · Pharmaceuticals

Diligence memoA one-page analyst read on Verona Pharma plc — recommendation, valuation, rhythm, risks.
$244.7M
Total raised · real
2
Rounds
4.5×
Latest step-up
Top 4%
Sector rank · raised
Series D+
Latest stage · inferred · Wed Jul 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Verona Pharma plc looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.87× the median modeled value of Series D+ Pharmaceuticals companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.9 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Verona Pharma plc is one of 1613 Pharmaceuticals companies tracked from London. By capital raised it ranks among the largest (ahead of 97% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

pharma

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
43
Investors (latest)
2020-07-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5B$5.0B$7.5B$10.0BSeries C · 2016-06-17 Raised $45M (real) Modeled valuation $1.6B (est)$45M$1.6BSeries C2016Series D+ · 2020-07-22 Raised $200M (real) Modeled valuation $7.0B (est)$200M$7.0BSeries D+2020+$200MCumulative $245M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$44.5M · 2016
Series D+$200.2M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$7.0B
Base estimate est.
$952.7M
Conservative case
$15.1B
Upside case
$1.7B
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series C · modeled $1.6B · 2016-06-172016Series D+ · modeled $7.0B · 2020-07-222020
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
71%
Survival probability
57% low · 79% high
1.35×/yr
Annual markup
1.51×/yr upside case
5.9 yr
Elapsed time used
5.9 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
49 mo
Avg between rounds
$59.7M/yr
Capital velocity
10.0 yr
On record since
2016
First round
2
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 30× above median
This company$244.7M
Sector median$8.1M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 1.8× above median
This company$200.2M
Sector median$111.8M
Modeled value — vs sector median (estimate, all stages) 91× above median
This company$7.0B
Sector median$76.1M

Raised more than 97% of sector peers (real $). Modeled value above 99% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #4 of 15.

This companyCohort peer
$1.0B$10.0B$100.0B$10.0M$100.0M$1.0BCapital raised (log)Nuvation Bio Inc. · Series D+ Raised $275.3M · modeled $9.7B (est)Recursion Pharmaceuticals, Inc. · Series D+ Raised $478.3M · modeled $8.3B (est)Vyripharm Enterprises, Inc. · Series D+ Raised $300.0M · modeled $7.2B (est)Cingulate Inc. · Series D+ Raised $220.0M · modeled $5.4B (est)Day One Biopharmaceuticals Holding Co LLC · Series D+ Raised $130.0M · modeled $3.9B (est)Design Therapeutics, Inc. · Series D+ Raised $170.5M · modeled $3.7B (est)Secura Bio Holdings, Inc. · Series D+ Raised $105.0M · modeled $3.7B (est)Revolution Medicines, Inc. · Series D+ Raised $204.2M · modeled $3.5B (est)Entrada Therapeutics, Inc. · Series D+ Raised $150.9M · modeled $3.3B (est)Catabasis Pharmaceuticals Inc · Series D+ Raised $349.6M · modeled $3.3B (est)DTx Pharma, Inc. · Series D+ Raised $113.4M · modeled $2.9B (est)Verona Pharma plc (this company) Raised $244.7M · modeled $7.0B (est)Verona Pharma plc
CompanyStageRaised · realValue · estvs peer med.
Nuvation Bio Inc.Series D+$275.3M$9.7B2.62×
Recursion Pharmaceuticals, Inc.Series D+$478.3M$8.3B2.23×
Vyripharm Enterprises, Inc.Series D+$300.0M$7.2B1.95×
Verona Pharma plc this companySeries D+$244.7M$7.0B1.87×
Cingulate Inc.Series D+$220.0M$5.4B1.45×
Day One Biopharmaceuticals Holding Co LLCSeries D+$130.0M$3.9B1.04×
Design Therapeutics, Inc.Series D+$170.5M$3.7B1.01×
Secura Bio Holdings, Inc.Series D+$105.0M$3.7B1.00×
Revolution Medicines, Inc.Series D+$204.2M$3.5B0.96×
Entrada Therapeutics, Inc.Series D+$150.9M$3.3B0.89×
Catabasis Pharmaceuticals IncSeries D+$349.6M$3.3B0.88×
DTx Pharma, Inc.Series D+$113.4M$2.9B0.79×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$44.5M2016-06-17$296.8M$1.6B85%
Series D+$200.2M2020-07-22$1.7B$7.0B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$44.5M2016-06-17
    • First recorded raise — entered as Series C.
    • 8 investors on this round.
  2. Series D+$200.2M2020-07-22
    • Raised again after 49 mo — slower than the ~13 mo sector norm.
    • Round 4.5× larger than the prior — scaling up.
    • 43 investors on this round.
Intelligence
2024 ~Q3
Modeled next raise · ~49mo cadence
$600.5M
Modeled next size est.range $390.3M$960.7M
4.5×
Last step-up
$59.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ken Cunningham2 other2016-06
David Zaccardelli1 other2020-07
Jan-Anders Karlsson1 other2016-06
Anders Ullman2016-06
Anders W. Ullman2020-07
Andrew W. Sinclair2020-07
Claire W. Poll2020-07
David Ebsworth2016-06
David W. Ebsworth2020-07
Kathleen W. Rickard2020-07
Kenneth Newman2016-06
Ken W. Cunningham2020-07
Mahendra W. Shah2020-07
Mark W. Hahn2020-07
Martin W. Edwards2020-07
Patrick Humphrey2016-06
Peter Spargo2016-06
Rishi W. Gupta2020-07
Vikas W. Sinha2020-07
Registry & provenance

Verona Pharma plc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1657312
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Eliem Therapeutics, Inc.PharmaceuticalsSeries D+$253.2M$1.3Bsame sector · same stage
Tesaro, Inc.PharmaceuticalsSeries D+$255.0M$1.8Bsame sector · same stage
Surterra Holdings, Inc./DEPharmaceuticalsSeries D+$230.4M$5.8Bsame sector · same stage
Concordia International Corp.PharmaceuticalsSeries D+$228.0M$8.1Bsame sector · same stage
Strongbridge Biopharma plcPharmaceuticalsSeries D+$220.6M$1.2Bsame sector · same stage
Cingulate Inc.PharmaceuticalsSeries D+$220.0M$5.4Bsame sector · same stage
Beam Therapeutics Inc.PharmaceuticalsSeries D+$218.6M$4.8Bsame sector · same stage
NovaBay Pharmaceuticals, Inc.PharmaceuticalsSeries D+$218.1M$913.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
PharmaCielo Ltd.PharmaceuticalsSeries A$195.6M81%
Pharmula Laboratories Inc.PharmaceuticalsPre-Seed$4.7M79%
Eikonoklastes Therapeutics, Inc.PharmaceuticalsSeries A$43.9M78%
Bryn Pharma, LLCPharmaSeries C$31.4M78%
Lamassu Pharma, LLCPharmaceuticalsSeed$101.5M78%
China Pharma Holdings, Inc.PharmaceuticalsSeries A$87.6M78%
Atlas Oncology Holdings Inc.PharmaSeries B$85.1M78%
PharmID, Inc.PharmaceuticalsSeries A$154.9M77%
Frequently asked
How much funding has Verona Pharma plc raised?
Verona Pharma plc has raised approximately $244.7M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Verona Pharma plc's estimated valuation?
Provath's modeled valuation for Verona Pharma plc is approximately $7.0B (modeled range $952.7M–$15.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Verona Pharma plc at?
Verona Pharma plc's latest modeled financing stage is Series D+. Its most recent recorded round closed around Wed Jul 22.
What does Verona Pharma plc do and where is it based?
Verona Pharma plc operates in the Pharmaceuticals sector, based in London.
Explore related

See where Verona Pharma plc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Verona Pharma plc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.